Louise Barys

2.1k total citations
12 papers, 575 citations indexed

About

Louise Barys is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Louise Barys has authored 12 papers receiving a total of 575 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Molecular Biology, 5 papers in Oncology and 3 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Louise Barys's work include Radiopharmaceutical Chemistry and Applications (2 papers), Colorectal Cancer Treatments and Studies (2 papers) and Chronic Myeloid Leukemia Treatments (2 papers). Louise Barys is often cited by papers focused on Radiopharmaceutical Chemistry and Applications (2 papers), Colorectal Cancer Treatments and Studies (2 papers) and Chronic Myeloid Leukemia Treatments (2 papers). Louise Barys collaborates with scholars based in Switzerland, United States and Canada. Louise Barys's co-authors include Sandra W. Cowan‐Jacob, Paul W. Manley, Heidi A. Lane, Cheryl A. Doughty, David J. Kwiatkowski, Saveur-Michel Maira, Christine Stephan, Madlaina Breuleux, Moriko Ito and William R. Sellers and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Louise Barys

12 papers receiving 572 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Louise Barys Switzerland	8	328	157	139	105	80	12	575
Saradhi Mallampati United States	14	275 0.8×	155 1.0×	75 0.5×	94 0.9×	40 0.5×	34	592
Donald P. Lesslie United States	8	397 1.2×	353 2.2×	96 0.7×	87 0.8×	58 0.7×	11	687
Eliza Vakana United States	12	497 1.5×	99 0.6×	164 1.2×	33 0.3×	115 1.4×	14	644
Karl Hsu United States	7	255 0.8×	168 1.1×	101 0.7×	80 0.8×	44 0.6×	14	433
Zhimin Gu United States	12	459 1.4×	169 1.1×	235 1.7×	62 0.6×	59 0.7×	20	642
Ricardo Parrondo United States	15	374 1.1×	255 1.6×	196 1.4×	92 0.9×	130 1.6×	75	698
Xiaosheng Fang China	15	300 0.9×	196 1.2×	57 0.4×	74 0.7×	99 1.2×	69	661
Jennifer Macaluso United States	8	350 1.1×	170 1.1×	132 0.9×	63 0.6×	60 0.8×	9	539
Zhihong Zeng United States	6	467 1.4×	111 0.7×	203 1.5×	54 0.5×	119 1.5×	13	652
Michael Andreef United States	10	316 1.0×	130 0.8×	342 2.5×	87 0.8×	133 1.7×	17	698

Countries citing papers authored by Louise Barys

Since Specialization

Citations

This map shows the geographic impact of Louise Barys's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Louise Barys with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Louise Barys more than expected).

Fields of papers citing papers by Louise Barys

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Louise Barys. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Louise Barys. The network helps show where Louise Barys may publish in the future.

Co-authorship network of co-authors of Louise Barys

This figure shows the co-authorship network connecting the top 25 collaborators of Louise Barys. A scholar is included among the top collaborators of Louise Barys based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Louise Barys. Louise Barys is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

Bono, Johann S. de, Michael J. Morris, Xiao X. Wei, et al.. (2025). Association of baseline and on-treatment ctDNA fraction with clinical outcomes in patients with mCRPC in the PSMAfore study of ¹⁷⁷ Lu-PSMA-617.. Journal of Clinical Oncology. 43(5_suppl). 16–16. 2 indexed citations

Mermet‐Meillon, Fanny, Judith Knehr, Ulrike Naumann, et al.. (2024). Protein destabilization underlies pathogenic missense mutations in ARID1B. Nature Structural & Molecular Biology. 31(7). 1018–1022. 4 indexed citations

Bono, Johann S. de, Michael J. Morris, Oliver Sartor, et al.. (2024). Baseline ctDNA analyses and associations with outcomes in taxane-naive patients with mCRPC treated with ¹⁷⁷Lu-PSMA-617 versus change of ARPI in PSMAfore.. Journal of Clinical Oncology. 42(16_suppl). 5008–5008. 7 indexed citations

Bauer, Todd M., Armando Santoro, Chia‐Chi Lin, et al.. (2023). Phase I/Ib, open-label, multicenter, dose-escalation study of the anti-TGF-β monoclonal antibody, NIS793, in combination with spartalizumab in adult patients with advanced tumors. Journal for ImmunoTherapy of Cancer. 11(11). e007353–e007353. 24 indexed citations

Ribrag, Vincent, Zev A. Wainberg, Lara Iglesias Docampo, et al.. (2022). Pharmacokinetic and pharmacodynamic activity evaluation of MAK683, a selective oral embryonic ectoderm development (EED) inhibitor, in adults with advanced malignancies in a first-in-human study.. Journal of Clinical Oncology. 40(16_suppl). 3083–3083. 2 indexed citations

Bauer, Todd M., Chia‐Chi Lin, Richard Greil, et al.. (2021). Phase Ib study of the anti-TGF-β monoclonal antibody (mAb) NIS793 combined with spartalizumab (PDR001), a PD-1 inhibitor, in patients (pts) with advanced solid tumors.. Journal of Clinical Oncology. 39(15_suppl). 2509–2509. 16 indexed citations

Schuld, Peter, Stephan Grzesiek, Judith Habazettl, et al.. (2020). Structural and Biochemical Studies Confirming the Mechanism of Action of Asciminib, an Agent Specifically Targeting the ABL Myristoyl Pocket (STAMP). Blood. 136(Supplement 1). 34–35. 8 indexed citations

Manley, Paul W., Louise Barys, & Sandra W. Cowan‐Jacob. (2020). The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase. Leukemia Research. 98. 106458–106458. 92 indexed citations

Craig, Vanessa J., Julius Gräsel, Barbara Schacher Engstler, et al.. (2016). Complementary activities of DOT1L and Menin inhibitors in MLL-rearranged leukemia. Leukemia. 31(6). 1269–1277. 84 indexed citations

10.

Michaloglou, Chrysiis, Typhaine Martin, Clara Delaunay, et al.. (2013). The Tyrosine Phosphatase PTPN14 Is a Negative Regulator of YAP Activity. PLoS ONE. 8(4). e61916–e61916. 69 indexed citations

11.

Ito, Moriko, Louise Barys, Terence O’Reilly, et al.. (2010). Comprehensive Mapping of p53 Pathway Alterations Reveals an Apparent Role for Both SNP309 and MDM2 Amplification in Sarcomagenesis. Clinical Cancer Research. 17(3). 416–426. 86 indexed citations

12.

Breuleux, Madlaina, Christine Stephan, Cheryl A. Doughty, et al.. (2009). Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition. Molecular Cancer Therapeutics. 8(4). 742–753. 181 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact